CN113088489A - 一种起始免疫细胞活化扩增体系及其应用 - Google Patents
一种起始免疫细胞活化扩增体系及其应用 Download PDFInfo
- Publication number
- CN113088489A CN113088489A CN202110467793.8A CN202110467793A CN113088489A CN 113088489 A CN113088489 A CN 113088489A CN 202110467793 A CN202110467793 A CN 202110467793A CN 113088489 A CN113088489 A CN 113088489A
- Authority
- CN
- China
- Prior art keywords
- cells
- medium
- cell
- activation
- tgf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000003321 amplification Effects 0.000 title claims abstract description 83
- 238000003199 nucleic acid amplification method Methods 0.000 title claims abstract description 83
- 230000005931 immune cell recruitment Effects 0.000 title claims abstract description 21
- 210000004027 cell Anatomy 0.000 claims abstract description 127
- 210000002865 immune cell Anatomy 0.000 claims abstract description 69
- 230000004913 activation Effects 0.000 claims abstract description 53
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims abstract description 52
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims abstract description 52
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims abstract description 52
- 238000000034 method Methods 0.000 claims abstract description 22
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims abstract description 19
- 230000003213 activating effect Effects 0.000 claims abstract description 9
- 239000002876 beta blocker Substances 0.000 claims abstract description 7
- 239000002609 medium Substances 0.000 claims description 71
- 239000001963 growth medium Substances 0.000 claims description 23
- 102000000588 Interleukin-2 Human genes 0.000 claims description 20
- 108010002350 Interleukin-2 Proteins 0.000 claims description 20
- 102000003812 Interleukin-15 Human genes 0.000 claims description 18
- 108090000172 Interleukin-15 Proteins 0.000 claims description 18
- 108010002586 Interleukin-7 Proteins 0.000 claims description 18
- 102000000704 Interleukin-7 Human genes 0.000 claims description 18
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 17
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 16
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 15
- 239000011550 stock solution Substances 0.000 claims description 12
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 9
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 9
- 239000007640 basal medium Substances 0.000 claims description 5
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 210000003289 regulatory T cell Anatomy 0.000 abstract description 33
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 20
- 238000002360 preparation method Methods 0.000 abstract description 18
- 230000001965 increasing effect Effects 0.000 abstract description 11
- 230000002829 reductive effect Effects 0.000 abstract description 10
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract description 8
- 230000001404 mediated effect Effects 0.000 abstract description 6
- 239000012636 effector Substances 0.000 abstract description 5
- 230000005714 functional activity Effects 0.000 abstract description 4
- 230000003832 immune regulation Effects 0.000 abstract description 4
- 230000007246 mechanism Effects 0.000 abstract description 4
- 230000003827 upregulation Effects 0.000 abstract description 4
- 230000001105 regulatory effect Effects 0.000 abstract description 3
- 238000002659 cell therapy Methods 0.000 abstract description 2
- 238000001994 activation Methods 0.000 description 44
- 238000005119 centrifugation Methods 0.000 description 24
- 238000004113 cell culture Methods 0.000 description 18
- 239000006285 cell suspension Substances 0.000 description 16
- 239000005557 antagonist Substances 0.000 description 15
- 239000006228 supernatant Substances 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 13
- 238000005070 sampling Methods 0.000 description 12
- 239000012981 Hank's balanced salt solution Substances 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 230000004083 survival effect Effects 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000004698 lymphocyte Anatomy 0.000 description 9
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 8
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 8
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 8
- 230000000259 anti-tumor effect Effects 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 229920001917 Ficoll Polymers 0.000 description 7
- 238000011467 adoptive cell therapy Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- 238000010257 thawing Methods 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 210000003162 effector t lymphocyte Anatomy 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000003306 harvesting Methods 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 210000004970 cd4 cell Anatomy 0.000 description 3
- 230000020411 cell activation Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000005138 cryopreservation Methods 0.000 description 3
- 239000012531 culture fluid Substances 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 238000011067 equilibration Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000013028 medium composition Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012642 immune effector Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002143 encouraging effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Dentistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Environmental Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
扩增培养基体积 | 2~4mL | 5~9mL | 10~15mL | 16~59mL | 60~120mL | 120~200mL |
培养容器规格 | 6孔 | 1×T25 | 2×T25 | 1×T75 | 1×T175 | 1×T225 |
扩增培养基体积 | 2~4mL | 5~9mL | 10~15mL | 16~59mL | 60~120mL | 120~200mL |
培养容器规格 | 6孔 | 1×T25 | 2×T25 | 1×T75 | 1×T175 | 1×T225 |
扩增培养基体积 | 2~4mL | 5~9mL | 10~15mL | 16~59mL | 60~120mL | 120~200mL |
培养容器规格 | 6孔 | 1×T25 | 2×T25 | 1×T75 | 1×T175 | 1×T225 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110467793.8A CN113088489B (zh) | 2021-04-28 | 2021-04-28 | 一种起始免疫细胞活化扩增体系及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110467793.8A CN113088489B (zh) | 2021-04-28 | 2021-04-28 | 一种起始免疫细胞活化扩增体系及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113088489A true CN113088489A (zh) | 2021-07-09 |
CN113088489B CN113088489B (zh) | 2022-01-07 |
Family
ID=76680586
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110467793.8A Active CN113088489B (zh) | 2021-04-28 | 2021-04-28 | 一种起始免疫细胞活化扩增体系及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113088489B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115747160A (zh) * | 2022-12-05 | 2023-03-07 | 贵州生诺生物科技有限公司 | 一种体外扩增冷冻保存的淋巴结抗肿瘤t细胞的方法及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109082410A (zh) * | 2017-08-18 | 2018-12-25 | 路春光 | 外周血单个核细胞诱导的记忆性免疫细胞及应用 |
CN109666639A (zh) * | 2018-12-24 | 2019-04-23 | 浙江大学 | 一种杀伤活性增强的nk细胞及其制备方法 |
-
2021
- 2021-04-28 CN CN202110467793.8A patent/CN113088489B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109082410A (zh) * | 2017-08-18 | 2018-12-25 | 路春光 | 外周血单个核细胞诱导的记忆性免疫细胞及应用 |
CN109666639A (zh) * | 2018-12-24 | 2019-04-23 | 浙江大学 | 一种杀伤活性增强的nk细胞及其制备方法 |
Non-Patent Citations (3)
Title |
---|
CHUTAMAS THEPMALEE ET AL.: "Suppression of TGF-β and IL-10 receptors on self-differentiated dendritic cells by short-hairpin RNAs enhanced activation of effector T-cells against cholangiocarcinoma cells", 《HUM VACCIN IMMUNOTHER》 * |
戴煜等: "免疫抑制疗法对急性再生障碍性贫血患儿Treg/Th17细胞的影响", 《广东医学》 * |
杨晓帆等: "系统性红斑狼疮患者外周血中调节性T细胞相关分子TGF-β表达缺陷的研究", 《南京医科大学学报(自然科学版)》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115747160A (zh) * | 2022-12-05 | 2023-03-07 | 贵州生诺生物科技有限公司 | 一种体外扩增冷冻保存的淋巴结抗肿瘤t细胞的方法及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN113088489B (zh) | 2022-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pierson et al. | CD56+ bright and CD56+ dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis | |
CN109536446B (zh) | 单核细胞增殖剂、单核细胞增殖用培养基、及单核细胞的制造方法 | |
CN107475192B (zh) | 一种以记忆干t细胞为主要成分的淋巴细胞群及其体外高效扩增方法 | |
CN111718899B (zh) | 一种冻存人pbmc复苏后体外诱导nk细胞的培养方法 | |
KR101521484B1 (ko) | 메모리 t세포를 주성분으로 하는 림프구 세포군의 제조 방법 | |
CN113151170B (zh) | 一种高纯度外周血cik细胞的培养方法 | |
CN105713879A (zh) | 一种用于脐带血造血干细胞扩增的培养体系及其应用 | |
CN113088489B (zh) | 一种起始免疫细胞活化扩增体系及其应用 | |
CN111500535B (zh) | 用于体外培养人自然杀伤细胞的方法和培养基 | |
CN111394308B (zh) | 一种脐带血淋巴细胞cik的培养方法 | |
CN113699107B (zh) | 一种外周血nkt细胞培养液及培养方法 | |
CN113549595A (zh) | 基于外周血的nk细胞体外培养方法 | |
CN111172110B (zh) | 一种脐带血cik细胞的培养方法 | |
WO2018211487A1 (en) | Selection and use of umbilical cord cell fractions suitable for transplantation | |
CN109628396B (zh) | 记忆性淋巴细胞群在肝癌治疗中的应用 | |
CN111117959A (zh) | Dc-cik细胞培养基、dc-cik细胞的培养方法及应用 | |
US11730771B2 (en) | Selection and use of umbilical cord cell fractions suitable for transplantation | |
CN108192866B (zh) | Sfn联合il-15和il-21制备记忆性t细胞的方法及应用 | |
EP2053123B1 (en) | Method of proliferating lak cell | |
CN113481157A (zh) | 特异性抗病毒过继免疫细胞的优化制备方法 | |
CN114107200B (zh) | 一种高纯度CD56+γδT细胞及其制备方法和用途 | |
CN116179486B (zh) | 一种肿瘤浸润淋巴细胞的制备方法 | |
CN106754702B (zh) | 细胞因子诱导杀伤细胞动态悬浮培养的方法 | |
CN116515751A (zh) | 一种自体特异性t细胞的体外扩增方法 | |
CN117417889A (zh) | 一种功能增强型dc-cik细胞的培养液及其培养方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhai Zhimin Inventor after: Gao Zhimai Inventor after: Li Cong Inventor after: Wang Huiping Inventor before: Zhai Zhimin |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231107 Address after: Room 101, east of the first floor of the second factory building, Intelligent Technology Park, No. 3963 Susong Road, Hefei Economic and Technological Development Zone, 230000, Anhui Province Patentee after: Shengzaoyuan Biotechnology Co.,Ltd. Address before: 230601 Furong Road 678, Hefei Economic and Technological Development Zone, Anhui Province Patentee before: THE SECOND HOSPITAL OF ANHUI MEDICAL University Patentee before: Lu Chao |
|
TR01 | Transfer of patent right |